替吉奥与黄芪多糖注射液联合用于头颈部肿瘤放疗的增效作用  

Synergistic Effect of Tegiol combined with Astragalus Polysaccharide Injection in Radiotherapy of Head and Neck Tumors

作　　者：吴仁瑞[1] 钟琼[1] 汪琛[1] WU Renrui;ZHONG Qiong;WANG Chen(Ganzhou People's Hospital, Jiangxi Ganzhou 341000, China)

机构地区：[1]江西省赣州市人民医院肿瘤科

出　　处：《河北医学》2019年第6期1023-1027,共5页Hebei Medicine

基　　金：2016年南昌市自然科学基金资助项目,(编号:81660199)

摘　　要：目的:观察替吉奥与黄芪多糖注射液联合用于头颈部肿瘤放疗的增效作用。方法:选取本院2015年7月至2017年7月收治的头颈部肿瘤患者86例,按随机数字表法分为观察组与对照组,各43例。对照组采取调强放疗,疗程5~7周,观察组在调强放疗基础上予替吉奥胶囊与黄芪多糖注射液。比较两组总缓解率、治疗前后的T细胞亚群(包括CD4+、CD8+、CD4+/CD8+)与自然杀伤细胞(NK)活性、黏膜损伤、皮炎损伤、口干、恶心呕吐、腹泻等毒副反应发生率。结果:观察组总缓解率为83.72%,高于对照组62.79%,差异有统计学意义(P<0.05)。对照组治疗前后的CD4+、CD8+、CD4+/CD8+、NK的差异无统计学意义(P>0.05);观察组治疗后的CD4+、CD4+/CD8+与NK均较治疗前增大,且高于对照组,差异有统计学意义(P<0.05);CD8+均较治疗前减小,且低于对照组,差异有统计学意义(P<0.05)。两组腹泻与恶心呕吐的严重程度分级的差异无统计学意义(P>0.05);观察组黏膜损伤、皮炎损伤、口干的严重程度分级低于对照组,差异有统计学意义(P<0.05)。结论:替吉奥联合黄芪多糖注射液可有效提高头颈部肿瘤患者的放疗疗效并增强患者免疫、减轻毒副反应,值得推广。Objective: To observe the synergistic effect of tegiol combined with astragalus polysaccharide injection in radiotherapy of head and neck tumors. Methods: A total of 86 cases of head and neck cancer patients admitted to our hospital from July 2015 to July 2017 were randomly divided into observation group and control group, with 43 cases in each group. The control group received intensity modulated radiation therapy, the course of treatment lasted for 5 to 7 weeks. The observation group was given the tegafur, gimeracil and oteracil potassium capsules and astragalus polysaccharide injection on the basis of intensity modulated radiation therapy. The total remission rate, T-cell subsets (including CD4+, CD8+, CD4+/CD8+) and natural killer (NK) activity before and after treatment, the incidences of mucosal damage, dermatitis, dry mouth, feel sick and vomit, and diarrhea were compared between the two groups. Results: The total remission rate in the observation group was 83.72%, which was higher than 62.79% in the control group, the difference was statistically significant (P<0.05). There were no significant difference in CD4+, CD8+, CD4+/CD8+, and NK before and after treatment in the control group (P>0.05). The CD4+, CD4+/CD8+, and NK in the observation group increased after treatment and were higher than those in the control group, with a significant difference (P<0.05);While the CD8+ was lower than before treatment and was lower than the control group, with a significant difference (P<0.05). There were no significant difference in the severity grades of diarrhea and feel sick and vomit between the two groups (P>0.05). The severity of mucosal injury, dermatitis injury and dry mouth in the observation group were lower than those in the control group, with a significant difference (P<0.05). Conclusion: The combination of tegafur, gimeracil and oteracil potassium capsules and astragalus polysaccharide injection can effectively improve the radiotherapy efficacy of patients with head and neck cancer, enhance patient immuni

关 键 词：头颈部肿瘤 替吉奥 黄芪多糖注射液 调强放疗 

分 类 号：R739.91[医药卫生—肿瘤]